AI Summary
We reviewed 153 live results for subcutaneous immune globulin and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Pharmaceuticals and Subcutaneous Immune Globulin.
Comparison Table
Recommended
XEMBIFY® (immune globulin subcutaneous, human–klhw) 20%
Source: Xembify
Description
XEMBIFY is a sterile, 20% liquid solution of human immune globulin G (IgG) indicated for the treatment of primary humoral immunodeficiency (PI) in adults and pediatric patients 2 years of age and older. This subcutaneous immune globulin (SCIG) replacement therapy is available in single-use glass vials in multiple sizes, including 1 g, 2 g, 4 g, and 10 g, to accommodate flexible dosing requirements and home administration.
Best for
primary humoral immunodeficiency treatment, patients 2 years and older, subcutaneous infusion therapy and home self-administration
View Details
Rating
Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid)
Source: CSL Behring
Description
Hizentra is the first and only 20% subcutaneous immunoglobulin (SCIg) therapy approved for the treatment of primary immunodeficiency (PI) and the maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). This human normal immunoglobulin solution is stabilized with L-proline and designed for convenient subcutaneous injection, allowing for patient self-administration at home with single-dose prefilled syringes or vials.
Best for
primary immunodeficiency patients, CIDP maintenance therapy, subcutaneous self-administration and home-based medical treatment
View Details
Rating
Cuvitru [Immune Globulin Subcutaneous (Human), 20% Solution]
Source: Takeda Healthcare Philippines, Inc.
Description
Cuvitru is a 200 mg/mL (20%) liquid protein solution indicated as replacement therapy for adults and pediatric patients (2 years and older) with primary humoral immunodeficiency (PI). This subcutaneous immunoglobulin (SCIG) treatment is designed for ready-to-use infusion with a maximum infusion rate of 60 mL/hr per site, allowing for flexible administration in clinical or home settings.
Best for
primary humoral immunodeficiency patients, pediatric patients 2 years and older, subcutaneous replacement therapy and home infusion management
View Details
Rating
| Compare | XEMBIFY® (immune globulin subcutaneous, human–klhw) 20% | Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) | Cuvitru [Immune Globulin Subcutaneous (Human), 20% Solution] |
|---|---|---|---|
| Source | Xembify | CSL Behring | Takeda Healthcare Philippines, Inc. |
| Description | XEMBIFY is a sterile, 20% liquid solution of human immune globulin G (IgG) indicated for the treatment of primary humoral immunodeficiency (PI) in adults and pediatric patients 2 years of age and older. This subcutaneous immune globulin (SCIG) replacement therapy is available in single-use glass vials in multiple sizes, including 1 g, 2 g, 4 g, and 10 g, to accommodate flexible dosing requirements and home administration. | Hizentra is the first and only 20% subcutaneous immunoglobulin (SCIg) therapy approved for the treatment of primary immunodeficiency (PI) and the maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). This human normal immunoglobulin solution is stabilized with L-proline and designed for convenient subcutaneous injection, allowing for patient self-administration at home with single-dose prefilled syringes or vials. | Cuvitru is a 200 mg/mL (20%) liquid protein solution indicated as replacement therapy for adults and pediatric patients (2 years and older) with primary humoral immunodeficiency (PI). This subcutaneous immunoglobulin (SCIG) treatment is designed for ready-to-use infusion with a maximum infusion rate of 60 mL/hr per site, allowing for flexible administration in clinical or home settings. |
| Best for | primary humoral immunodeficiency treatment, patients 2 years and older, subcutaneous infusion therapy and home self-administration | primary immunodeficiency patients, CIDP maintenance therapy, subcutaneous self-administration and home-based medical treatment | primary humoral immunodeficiency patients, pediatric patients 2 years and older, subcutaneous replacement therapy and home infusion management |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"XEMBIFY® (immune globulin subcutaneous, human–klhw) 20% from Xembify."
I picked this because Xembify provides a high-concentration 20% IgG solution with multiple vial size options, making it a versatile choice for patients seeking subcutaneous therapy for primary immunodeficiency.
Share this search
Related Finds